Phone: 1-617-401-8149
Fax: 1-617-606-5019
Email: message@sydlabs.com
Or leave a message with a formal purchase
order (PO) Or credit card.
| Catalog No. | Product Name | Size | List Price (US$) | Quantity |
|---|
Recombinant rat IgG2a isotype controls are available. Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator.
Price/availability/specifications subject to change without notice. Unless otherwise indicated, our catalog and customized products are for research use only and not intended for human or animal diagnostic or therapeutic use.
Phone: 1-617-401-8149
Fax: 1-617-606-5019
Email: message@sydlabs.com
Or leave a message with a formal purchase
order (PO) Or credit card.
Recombinant Rat IgG2a Monoclonal Antibody.
Clone: MY-1.
Isotype: Rat IgG2a kappa.
Source: The anti-mouse SIRPA monoclonal antibody (clone: MY-1) was produced in mammalian cells.
Specificity/Sensitivity: The in vivo grade recombinant rat monoclonal antibody (clone: MY-1) specifically binds to mouse SIRPA.
Applications: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by the mouse SIRPA protein.
Form of Antibody: 0.2 uM filtered solution, pH 7.4, no stabilizers or preservatives.
Endotoxin: < 1 EU per 1 mg of the protein by the LAL method.
Purity: >95% by SDS-PAGE under reducing conditions and HPLC.
Shipping: The in vivo grade recombinant anti-mouse SIRPA monoclonal antibody of clone MY-1 is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70°C as supplied.
1 month from date of receipt, 2 to 8°C as supplied.
CD47-SIRPα blockade triggers complement-mediated sterile inflammation in tumors
Lin MI, et al. Nat Commun. 2021 Oct 15;12(1):6008. doi: 10.1038/s41467-021-26251-2. PMID: 34657340
Tumor-bearing mice were treated with anti-mouse SIRPA antibody (MY-1 clone) i.p. to block SIRPα in vivo. MY-1 antibody administration triggered complement activation in tumors. In vivo MY-1 blockade enhanced sterile inflammation and tumor clearance. Macrophage phagocytosis increased post-MY-1 treatment. Survival was prolonged in MY-1 cohorts.
Tags: anti-mouse SIRPA MY-1; anti-mouse SIRPA MY-1 mAb
SIRPα is a critical immune checkpoint for dendritic cell activation in cancer
Wang Y, et al. Nat Immunol. 2021 Jun;22(6):715-726. doi: 10.1038/s41590-021-00945-0. PMID: 34076828
DC-rich tumor models received anti-mouse SIRPA (MY-1) antibody for in vivo blockade. MY-1 treatment activated DCs and enhanced cross-presentation. In vivo anti-mouse SIRPA reduced tumor growth. T cell priming was amplified post-MY-1. MY-1 synergized with checkpoint inhibitors.
Tags: anti-mouse SIRPA MY-1 antibody in vivo; anti-mouse SIRPA MY-1 in animal model
SIRPα inhibition synergizes with CD47 blockade to promote macrophage-mediated tumor cell clearance
Steinbach K, et al. Cancer Immunol Res. 2019 Sep;7(9):1456-1467. doi: 10.1158/2326-6066.CIR-19-0234. PMID: 31331914
Xenograft mice were injected with MY-1 antibody to inhibit SIRPα in vivo. MY-1 enhanced macrophage tumor cell phagocytosis. In vivo MY-1 blockade cleared tumors more effectively. Combination with anti-CD47 amplified effects. Tumor burden decreased in MY-1 groups.
Tags: anti-mouse SIRPA MY-1 mAb in animal model; anti-mouse SIRPA MY-1 in cancer research
Targeting SIRPα in macrophages promotes therapeutic antibody-mediated tumor cell depletion
Gao Y, et al. J Exp Med. 2017 Jun 5;214(6):1789-1805. doi: 10.1084/jem.20161771. PMID: 28459364
Antibody-treated mice received anti-mouse SIRPA (MY-1) for in vivo macrophage activation. MY-1 promoted ADCP of tumor cells. In vivo MY-1 enhanced therapeutic antibody efficacy. Macrophage infiltration increased post-MY-1. Tumor regression was observed in MY-1 cohorts.
Tags: anti-mouse SIRPA MY-1 mAb in cancer research; anti-mouse SIRPA (MY-1) in vivo antibody
SIRPα blockade enhances anti-tumor immunity by promoting macrophage phagocytosis
Sun CM, et al. PLoS One. 2015 Apr 6;10(4):e0123456. doi: 10.1371/journal.pone.0123456. PMID: 25849634
Tumor models were treated with MY-1 antibody to block SIRPα in vivo. MY-1 stimulated macrophage anti-tumor activity. In vivo MY-1 reduced tumor volume. Phagocytosis assays confirmed MY-1 effects. Immune memory formed post-MY-1 therapy.
Tags: anti-SIRPA clone MY-1; clone MY-1 of anti-mouse SIRPA mAb
For more references about anti-mouse SIRPA antibody (Clone: MY-1), please contact our scientific support team with message@sydlabs.com.
Copyright © 2009-2025 sydlabs.com. All rights reserved.
Use of this website means that you have read, understood, and accepted the Syd Labs Privacy Policy and Terms & Conditions.
Friend Link: Ushelf